Navigation Links
Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
Date:3/18/2009

uding a reduction in workforce, taking employees from 194 as of December 31, 2008 to 85 employees by early second quarter of 2009 resulting from CTI's planned closure of its Bresso, Italy pre-clinical research operation and employees associated with Zevalin. CTI recently sold its remaining 50% interest in the Zevalin joint venture to Spectrum Pharmaceuticals for approximately $16.5 million.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone and OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone and OPAXIO in particular, including, without limitation, our ability to submit an NDA in the first half of 2009 for pixantrone and gain approval in 2009, the potential failure of these products to prove safe and effective for treatment of relapsed aggressive NHL, non-small cell lung cancer and ovarian cancer, determinations by regulatory, patent and administrative governmental authorities, that the forecast estimates for the potential sales will be achieved, the Company's ability to continue to raise capital as needed to fund its operations, competitive fact
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the ... received a Canadian Patent for Inhibition or Reversal ... includes claims using thymosin beta 4, various fragments ... these purposes.  The patent will expire in 2021. ... www.regenerx.com ) RegeneRx is focused ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
(Date:9/30/2014)... The custom stainless steel fabrication company HOLLOWAY ... The Boston Area Chapter of ISPE (International Society for ... for Wed., Oct. 1 at Gillette Stadium Clubhouse in ... in ISPE Boston’s long history, with more than 375 ... , HOLLOWAY AMERICA President David Simpson is looking ...
(Date:9/30/2014)... 30, 2014 UFP Technologies, a ... packaging has recently introduced a custom insulated shipping ... . The new insulated shipper solves the issue ... process. UFP Technologies’ BioShell is a universal storage ... storage, handling and shipping. The insulated shipper keeps ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3
... Smilodon ranks alongside Tyrannosaurus rex as the ultimate killing ... was a fearsome predator of Ice-Age America,s lost giants. ... debated how this iconic predator used its ferocious fangs ... published today in the US Proceedings of the National ...
... 1 Boston Scientific,Corporation (NYSE: BSX ) will ... quarter ended September 30, 2007 on Friday,October 19, at ... by Jim Tobin, President and Chief Executive,Officer, Paul LaViolette, ... Chief Financial Officer. The live webcast and archived ...
... Space Center,has awarded a five-year, $120-million extension of ... Institute, also known,as NSBRI, of Houston. Under the ... continue biomedical research in support of a,long-term human ... the cooperative agreement began April 1, 1997, with,a ...
Cached Biology Technology:Scientists say sabercat bit like a pussycat 2Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 2
(Date:9/30/2014)... in almost any aquatic environment on Earth, but when ... are pushed to the limit. The amount of time ... for how different species cope in the future, reveals ... Gothenburg, published in the scientific journal Proceedings of ... apace thanks to increasing levels of greenhouse gases in ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... Calif. Beyond the personal tragedy of chronic alcoholism ... know severe alcoholism stresses the heart and that mitochondria, ... But they don,t know the precise mechanism. Now ... Center of the New York State Department of Health ...
... 22, 2012 -- The first clinical trial of a ... by the Infectious Disease Research Institute (IDRI), a Seattle-based ... diseases of poverty. The Phase 1 trial is taking ... trial planned in India, an epicenter of the disease. ...
... an outbreak of airborne H5N1 influenza in humans needs to ... can safely continue H5N1 research and share the results among ... mBio , the online open-access journal of the American Society ... been at the center of heated discussions in science and ...
Cached Biology News:A change of heart 2First vaccine against fatal visceral leishmaniasis enters clinical trial 2First vaccine against fatal visceral leishmaniasis enters clinical trial 3Opinion: H5N1 flu is just as dangerous as feared, now requires action 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 3
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Latanoprost EIA Antiserum EIAs neutrophils antisera enzyme immunoassays reagents...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: